Menu

Stem Cells for In Vitro Modeling of Neurological Disease

The Scientist is bringing together a panel of experts to examine the potential of stem cells for in vitro modeling of neurological disease.

Aug 16, 2019
The Scientist Creative Services Team

FREE Webinar

Wednesday, October 9, 2019
2:30 - 4:00 PM Eastern Time

Register Now

Stem cells are valuable for neurological disease research and drug development as they permit the in vitro construction of disease models. Human pluripotent stem cells (hPSCs), including human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (ESCs), offer unique advantages for developmental studies. They can be employed in a patient-specific way to identify molecular lesions and aid in therapeutic development. To examine the potential of stem cells for in vitro modeling of neurological disease, The Scientist is bringing together a panel of experts to discuss their research and provide insight into these exciting techniques.

Topics to be covered:

  • Investigating the dynamic nature of the brain in the context of disease and injury using stem cell biology
  • Neurological disease modeling with induced pluripotent stem cells

Register Now

Meet the Speakers:

Jaime Imitola, MD
Director, Multiple Sclerosis and Translational Neuroimmunology
UConn Health


Mark E. Hester, PhD
Principal Investigator, Institute for Genomic Medicine
Abigail Wexner Research Institute, Nationwide Children’s Hospital, Ohio
Assistant Professor, Department of Pediatrics
The Ohio State University College of Medicine



September 2019

Our Inner Neanderthal

Ancient secrets in the human genome

Marketplace

Sponsored Product Updates

Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Download this application note to learn how the ACEA xCELLigence system can evaluate the potency of an immunotherapy against a broad spectrum of liquid tumors and monitor the destruction kinetics of liquid cancers at physiologically relevant effector:target cell ratios.
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Watch this webinar to learn how Dr. Cara Haymaker and her team are assessing the reactivity of tumor-infiltrating lymphocytes and modulating the mechanisms of resistance to therapy and exploring biomarkers involved in the response.
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs). Portfolio includes novel CIMasphere™ technology for higher yielding processes and safer products in AAV-based programs